Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
Silvia Sookoian, Carlos J. Pirola
Clin Mol Hepatol. 2020;26(4):461-475.   Published online 2020 Sep 10     DOI: https://doi.org/10.3350/cmh.2020.0136
Citations to this article as recorded by Crossref logo
Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
Chander K. Negi, Pavel Babica, Lola Bajard, Julie Bienertova-Vasku, Giovanni Tarantino
Metabolism.2022; 126: 154925.     CrossRef
Effects of PNPLA3 , TM6SF2 and SAMM50 on the development and severity of non‐alcoholic
Kyung Jae Lee, Jin Soo Moon, Nan Young Kim, Jae Sung Ko
Pediatric Obesity.2022;[Epub]     CrossRef
Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications
Carlos J. Pirola, Silvia Sookoian
Current Opinion in Lipidology.2022; 33(2): 95.     CrossRef
Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis
Ali Mahmoudi, Alexandra E. Butler, Muhammed Majeed, Maciej Banach, Amirhossein Sahebkar
Nutrients.2022; 14(7): 1331.     CrossRef
TissueSpace: a web tool for rank-based transcriptome representation and its applications in molecular medicine
Yiruo He, Wei Liu
Genes & Genomics.2022; 44(7): 793.     CrossRef
Intrahepatic inflammatory IgA+PD-L1high monocytes in hepatocellular carcinoma development and immunotherapy
Pil Soo Sung, Dong Jun Park, Pu Reun Roh, Kyoung Do Mun, Sung Woo Cho, Gil Won Lee, Eun Sun Jung, Sung Hak Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Jonghwan Choi, Jaegyoon Ahn, Seung Kew Yoon
Journal for ImmunoTherapy of Cancer.2022; 10(5): e003618.     CrossRef
Precision medicine in nonalcoholic fatty liver disease
Amedeo Lonardo
Journal of Gastroenterology and Hepatology.2022; 37(7): 1175.     CrossRef
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Nicholas W. S. Chew, Cheng Han Ng, Emily Truong, Mazen Noureddin, Kris V. Kowdley
Seminars in Liver Disease.2022; 42(03): 379.     CrossRef
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N
Journal of Hepatology.2022; 77(6): 1482.     CrossRef
Personalized medicine in nonalcoholic fatty liver disease
Carlos J. Pirola, Silvia Sookoian
Clinical and Molecular Hepatology.2022; 28(4): 935.     CrossRef
Pleiotropy within gene variants associated with nonalcoholic fatty liver disease and traits of the hematopoietic system
Carlos Jose Pirola, Adrian Salatino, Silvia Sookoian
World Journal of Gastroenterology.2021; 27(4): 305.     CrossRef
The lipidome in nonalcoholic fatty liver disease: actionable targets
Carlos J. Pirola, Silvia Sookoian
Journal of Lipid Research.2021; 62: 100073.     CrossRef
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Marco Arrese, Juan P. Arab, Francisco Barrera, Benedikt Kaufmann, Luca Valenti, Ariel E. Feldstein
Seminars in Liver Disease.2021; 41(04): 421.     CrossRef
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim, Jin-Woo Lee
Clinical and Molecular Hepatology.2021; 27(2): 257.     CrossRef
Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease
Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Tracey G. Simon, Andrew T. Chan, Seong Gyu Hwang
Scientific Reports.2021;[Epub]     CrossRef
Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management
Amedeo Lonardo, Juan Pablo Arab, Marco Arrese
Advances in Therapy.2021; 38(5): 2130.     CrossRef
Genetic risk scores and personalization of care in fatty liver disease
Cristiana Bianco, Federica Tavaglione, Stefano Romeo, Luca Valenti
Current Opinion in Pharmacology.2021; 61: 6.     CrossRef
NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions
Carlos J. Pirola, Silvia Sookoian
Hepatology.2021; 73(2): 479.     CrossRef
Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis
Ali Mahmoudi, Alexandra E. Butler, Tannaz Jamialahmadi, Amirhossein Sahebkar, Bing Niu
BioMed Research International.2021; 2021: 1.     CrossRef
Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
Emir Muzurović, Brigita Smolović, Snežana Vujošević, Milan Petakov
Current Vascular Pharmacology.2021; 19(5): 582.     CrossRef